The combination treatment of NKG2D CAR-NK cells with CD73 targeting demonstrates enhanced anti-tumor cytotoxicity in vitro and in vivo, indicating a potential alleviation from adenosinergic immune-metabolic suppression (47). This evidence concerns the gene KLRK1 and neoplasm.